Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel–Lindau Disease and Multiple Endocrine Neoplasia Type 2
Open Access
- 17 June 1999
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (24) , 1872-1879
- https://doi.org/10.1056/nejm199906173402404
Abstract
The detection of pheochromocytomas in patients at risk for these tumors, such as patients with von Hippel–Lindau disease or multiple endocrine neoplasia type 2 (MEN-2), is hindered by the inadequate sensitivity of commonly available biochemical tests. In this study we evaluated measurements of plasma normetanephrine and metanephrine for detecting pheochromocytomas in patients with von Hippel–Lindau disease or MEN-2. We studied 26 patients with von Hippel–Lindau disease and 9 patients with MEN-2 who had histologically verified pheochromocytomas and 50 patients with von Hippel–Lindau disease or MEN-2 who had no radiologic evidence of pheochromocytoma. Von Hippel–Lindau disease and MEN-2 were diagnosed on the basis of germ-line mutations of the appropriate genes. The plasma concentrations of normetanephrine and metanephrine were compared with the plasma concentrations of catecholamines (norepinephrine and epinephrine) and urinary excretion of catecholamines, metanephrines, and vanillylmandelic acid. The sensitivity of measurements of plasma normetanephrine and metanephrine for the detection of tumors was 97 percent, whereas the other biochemical tests had a sensitivity of only 47 to 74 percent. All patients with MEN-2 had high plasma concentrations of metanephrine, whereas the patients with von Hippel–Lindau disease had almost exclusively high plasma concentrations of only normetanephrine. One patient with von Hippel–Lindau disease had a normal plasma normetanephrine concentration; this patient had a very small adrenal tumor (<1 cm). The high sensitivity of measurements of plasma normetanephrine and metanephrine was accompanied by a high level of specificity (96 percent). Measurements of plasma normetanephrine and metanephrine are useful in screening for pheochromocytomas in patients with a familial predisposition to these tumors.Keywords
This publication has 30 references indexed in Scilit:
- Mesenteric Organ Production, Hepatic Metabolism, and Renal Elimination of Norepinephrine and Its Metabolites in HumansJournal of Neurochemistry, 1996
- Regional release and removal of catecholamines and extraneuronal metabolism to metanephrinesJournal of Clinical Endocrinology & Metabolism, 1995
- The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in ratsJournal of the Autonomic Nervous System, 1994
- Biochemical detection of phaeochromocytoma: should we still be measuring urinary HMMA?Journal of Clinical Pathology, 1993
- Biochemical diagnosis of phaeochromocytoma: two instructive case reports.Journal of Clinical Pathology, 1993
- Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statementEuropean Journal of Clinical Investigation, 1992
- High permanent plasma adrenaline levels: a marker of adrenal medullary disease in medullary thyroid carcinomaClinical Endocrinology, 1991
- The Clinical Outcome of Prospective Screening for Multiple Endocrine Neoplasia Type 2ANew England Journal of Medicine, 1988
- Measurement of urinary epinephrine in screening for pheochromocytoma in multiple endocrine neoplasia type IIThe American Journal of Medicine, 1978
- High epinephrine content in the adrenal tumors from Sipple's syndrome.The Tohoku Journal of Experimental Medicine, 1975